MLLCF
Price
Loading...
Change
-$0.00 (-0.00%)
Updated
Loading...
Capitalization
154.82M
Intraday BUY SELL Signals
URGN
Price
$24.35
Change
-$0.03 (-0.12%)
Updated
Dec 3 closing price
Capitalization
1.14B
98 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

MLLCF vs URGN

Header iconMLLCF vs URGN Comparison
Open Charts MLLCF vs URGNBanner chart's image
Molecular Partners AG
PriceLoading...
Change-$0.00 (-0.00%)
Volume$2K
Capitalization154.82M
UroGen Pharma
Price$24.35
Change-$0.03 (-0.12%)
Volume$730.05K
Capitalization1.14B
MLLCF vs URGN Comparison Chart in %
MLLCF
Daily Signal:
Gain/Loss:
URGN
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
MLLCF vs. URGN commentary
Dec 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MLLCF is a Hold and URGN is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 04, 2025
Stock price -- (MLLCF: $3.60 vs. URGN: $24.36)
Brand notoriety: MLLCF and URGN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MLLCF: 183% vs. URGN: 59%
Market capitalization -- MLLCF: $154.82M vs. URGN: $1.14B
MLLCF [@Biotechnology] is valued at $154.82M. URGN’s [@Biotechnology] market capitalization is $1.14B. The market cap for tickers in the [@Biotechnology] industry ranges from $117.5B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MLLCF’s FA Score shows that 0 FA rating(s) are green whileURGN’s FA Score has 0 green FA rating(s).

  • MLLCF’s FA Score: 0 green, 5 red.
  • URGN’s FA Score: 0 green, 5 red.
According to our system of comparison, URGN is a better buy in the long-term than MLLCF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MLLCF’s TA Score shows that 4 TA indicator(s) are bullish while URGN’s TA Score has 3 bullish TA indicator(s).

  • MLLCF’s TA Score: 4 bullish, 1 bearish.
  • URGN’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, MLLCF is a better buy in the short-term than URGN.

Price Growth

MLLCF (@Biotechnology) experienced а 0.00% price change this week, while URGN (@Biotechnology) price change was -12.03% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.32%. For the same industry, the average monthly price growth was +1.23%, and the average quarterly price growth was +54.93%.

Reported Earning Dates

URGN is expected to report earnings on Mar 12, 2026.

Industries' Descriptions

@Biotechnology (+0.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
URGN($1.14B) has a higher market cap than MLLCF($155M). URGN YTD gains are higher at: 128.732 vs. MLLCF (-12.409). MLLCF has higher annual earnings (EBITDA): -62.52M vs. URGN (-119.79M). URGN has more cash in the bank: 196M vs. MLLCF (114M). MLLCF has less debt than URGN: MLLCF (1.84M) vs URGN (125M). URGN has higher revenues than MLLCF: URGN (91.9M) vs MLLCF (681K).
MLLCFURGNMLLCF / URGN
Capitalization155M1.14B14%
EBITDA-62.52M-119.79M52%
Gain YTD-12.409128.732-10%
P/E RatioN/AN/A-
Revenue681K91.9M1%
Total Cash114M196M58%
Total Debt1.84M125M1%
FUNDAMENTALS RATINGS
MLLCF vs URGN: Fundamental Ratings
MLLCF
URGN
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
45
Fair valued
60
Fair valued
PROFIT vs RISK RATING
1..100
10079
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
7634
P/E GROWTH RATING
1..100
81100
SEASONALITY SCORE
1..100
8550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MLLCF's Valuation (45) in the null industry is in the same range as URGN (60) in the Biotechnology industry. This means that MLLCF’s stock grew similarly to URGN’s over the last 12 months.

URGN's Profit vs Risk Rating (79) in the Biotechnology industry is in the same range as MLLCF (100) in the null industry. This means that URGN’s stock grew similarly to MLLCF’s over the last 12 months.

MLLCF's SMR Rating (97) in the null industry is in the same range as URGN (100) in the Biotechnology industry. This means that MLLCF’s stock grew similarly to URGN’s over the last 12 months.

URGN's Price Growth Rating (34) in the Biotechnology industry is somewhat better than the same rating for MLLCF (76) in the null industry. This means that URGN’s stock grew somewhat faster than MLLCF’s over the last 12 months.

MLLCF's P/E Growth Rating (81) in the null industry is in the same range as URGN (100) in the Biotechnology industry. This means that MLLCF’s stock grew similarly to URGN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MLLCFURGN
RSI
ODDS (%)
Bearish Trend 7 days ago
50%
Bearish Trend 7 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 7 days ago
61%
Bearish Trend 7 days ago
90%
Momentum
ODDS (%)
N/A
N/A
MACD
ODDS (%)
N/A
N/A
TrendWeek
ODDS (%)
Bullish Trend 7 days ago
41%
Bullish Trend 7 days ago
84%
TrendMonth
ODDS (%)
Bullish Trend 7 days ago
38%
Bullish Trend 7 days ago
81%
Advances
ODDS (%)
N/A
Bullish Trend 9 days ago
82%
Declines
ODDS (%)
N/A
Bearish Trend 17 days ago
86%
BollingerBands
ODDS (%)
N/A
Bearish Trend 7 days ago
87%
Aroon
ODDS (%)
Bullish Trend 7 days ago
66%
Bullish Trend 7 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
MLLCF
Daily Signal:
Gain/Loss:
URGN
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SNROF34.81N/A
N/A
Sanrio Co. Ltd.
DBSDY166.70N/A
N/A
DBS Group Holdings Ltd.
GLATF0.37N/A
N/A
Global Atomic Corp.
TBBA6.26N/A
N/A
TEB Bancorp Inc.
HMNTY18.00N/A
N/A
HEMNET GROUP AB

MLLCF and

Correlation & Price change

A.I.dvisor indicates that over the last year, MLLCF has been loosely correlated with ENSC. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if MLLCF jumps, then ENSC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MLLCF
1D Price
Change %
MLLCF100%
N/A
ENSC - MLLCF
37%
Loosely correlated
-4.57%
CYYNF - MLLCF
31%
Poorly correlated
N/A
HNSBF - MLLCF
27%
Poorly correlated
N/A
URGN - MLLCF
26%
Poorly correlated
-14.41%
GNPX - MLLCF
24%
Poorly correlated
-4.91%
More

URGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, URGN has been loosely correlated with AIM. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if URGN jumps, then AIM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To URGN
1D Price
Change %
URGN100%
-14.41%
AIM - URGN
39%
Loosely correlated
-9.68%
CYYNF - URGN
38%
Loosely correlated
N/A
PHAT - URGN
37%
Loosely correlated
-1.27%
RVMD - URGN
35%
Loosely correlated
-0.65%
CVAC - URGN
34%
Loosely correlated
-1.54%
More